Parallax Volatility Advisers
BMRN icon

Parallax Volatility Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Parallax Volatility Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,000
Closed -$495K – 1609
2025
Q2 		$495K Sell
9,000
-37,500
-81% -$2.21M ﹤0.01% 1191
2025
Q1 		$3.29M Sell
46,500
-33,600
-42% -$2.26M 0.01% 732
2024
Q4 		$5.26M Buy
80,100
+13,500
+20% +$904K 0.01% 802
2024
Q3 		$4.68M Sell
66,600
-104,200
-61% -$8.71M 0.01% 818
2024
Q2 		$14.1M Buy
170,800
+110,000
+181% +$9.16M 0.03% 379
2024
Q1 		$5.31M Sell
60,800
-6,600
-10% -$591K 0.01% 715
2023
Q4 		$6.5M Buy
67,400
+7,200
+12% +$637K 0.01% 745
2023
Q3 		$5.33M Buy
60,200
+35,700
+146% +$3.18M 0.01% 740
2023
Q2 		$2.12M Sell
24,500
-43,400
-64% -$4.08M ﹤0.01% 1115
2023
Q1 		$6.6M Sell
67,900
-34,000
-33% -$3.52M 0.01% 738
2022
Q4 		$10.5M Buy
101,900
+4,800
+5% +$451K 0.02% 752
2022
Q3 		$8.23M Buy
97,100
+97,000
+97,000% +$8.64M 0.01% 825
2022
Q2 		$8K Sell
100
-200
-67% -$15.9K ﹤0.01% 2690
2022
Q1 		$23K Buy
+300
New +$25.1K ﹤0.01% 2586
2020
Q4 		– Sell
-74,000
Closed -$5.63M – 2472
2020
Q3 		$5.63M Sell
74,000
-16,100
-18% -$1.63M ﹤0.01% 1253
2020
Q2 		$11.1M Buy
90,100
+48,400
+116% +$4.81M 0.01% 733
2020
Q1 		$3.52M Buy
+41,700
New +$3.59M ﹤0.01% 1005
2019
Q2 		– Sell
-13,500
Closed -$1.2M – 2584
2019
Q1 		$1.2M Sell
13,500
-15,700
-54% -$1.46M ﹤0.01% 1194
2018
Q4 		$2.49M Hold
29,200
– – ﹤0.01% 972
2018
Q3 		$2.83M Hold
29,200
– – ﹤0.01% 913
2018
Q2 		$2.75M Buy
+29,200
New +$2.56M ﹤0.01% 803
2016
Q1 		– Sell
-100,000
Closed -$10.5M – 2525
2015
Q4 		$10.5M Buy
100,000
+75,000
+300% +$7.83M 0.02% 447
2015
Q3 		$2.63M Hold
25,000
– – 0.01% 900
2015
Q2 		$3.42M Buy
+25,000
New +$3.1M 0.01% 859

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Parallax Volatility Advisers's BMRN Position: Q2 2025 in Review

Parallax Volatility Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 14,133 shares — an estimated $832K sold.

Parallax Volatility Advisers first reported a position in BMRN in Q1 2014 and held it in 18 quarters. The position peaked at $2.54M in Q2 2019. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Parallax Volatility Advisers reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 14,133 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $832K.
  • Parallax Volatility Advisers first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 18 quarters.
  • Parallax Volatility Advisers's BioMarin Pharmaceuticals position peaked at $2.54M in Q2 2019.
  • 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Parallax Volatility Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.